SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE III CLINICAL STUDY OF "SEMAGLUTIDE INJECTION"

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Phase III clinical study of "Semaglutide Injection" developed by the Group has been initiated in China for the treatment of type 2 diabetes mellitus.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue with 94% sequence homology to human GLP-1, a polypeptide secreted by L cells in the small intestine, which has various functions such as increasing insulin synthesis and secretion, suppressing appetite, and slowing gastric emptying. Semaglutide lowers blood sugar by stimulating insulin secretion and decreasing glucagon secretion.

Semaglutide is the first GLP-1 weekly preparation in China with both hypoglycemic and cardiovascular indications, and its effects on blood glucose reduction, weight loss, protection against diabetic cardiovascular and cerebrovascular problems have been fully demonstrated. Compared with the last generation of hypoglycemic drugs, semaglutide has the prominent advantage of longer half-life and once-a-week administration, which greatly improves the medication compliance of patients. At present, semaglutide has become one of the best-selling hypoglycemic drugs in the world, with global sales exceeding US$10 billion in 2022.

This Phase III clinical study, led by Professor Dalong Zhu from Nanjing Drum Tower Hospital (the Affiliated Hospital of Nanjing University Medical School), is planned to enroll 492 patients to evaluate the efficacy and safety of semaglutide injection in patients with type 2 diabetes mellitus, with the primary endpoint being the level of glycosylated hemoglobin (HbA1c) after 32 weeks of treatment, and the secondary endpoints include blood lipids, fasting blood glucose, body weight, and drug safety.

In addition to semaglutide injection, application for the Phase Ib/II clinical trial of the Group's GMA106 (GIPR antagonist/GLP-1R agonist) has been submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China and has been accepted, which is expected to provide more drug options to patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 16 January 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.